Corsair Gaming Inc vs Heron Therapeutics Inc — how do they compare? Corsair Gaming Inc trades at $12.95 (market cap $1.39B), while Heron Therapeutics Inc trades at $0.34 (market cap $61.47M). The key difference: Corsair Gaming Inc is far larger — about 22.6× Heron Therapeutics Inc's market cap, and Corsair Gaming Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| CRSR | HRTX | |
|---|---|---|
Market Cap | $1.39B | $61.47M |
Sector | Technology | Health |
52-Week High | $14.35 | $1.49 |
52-Week Low | $4.58 | $0.32 |
Enterprise Value | $1.38B | $168.21M |
Signals from Pluang's Aura AI — not financial advice
Corsair Gaming (CRSR) trades at $12.96, down 5.47% today, but maintains a bullish technical signal with strong moving average support. Recent Q2 2026 earnings beat expectations with EPS of $0.23 versus $0.07 expected, and the company raised full-year guidance. Revenue for 2025 was $1.47 billion, though net income was negative $16.16 million, reflecting a net margin of -1.1%. The stock's valuation shows a P/E of 41.39 and P/S of 0.95, with analyst consensus leaning toward Hold but with a $12.40 price target slightly below current levels.
The outlook for CRSR is mixed; strong earnings beats and raised guidance signal operational improvement, but profitability remains a challenge with inconsistent net income. Key risks include competitive pressures in gaming hardware and reliance on consumer spending cycles. Upside potential hinges on sustained margin expansion and successful integration of recent acquisitions like Trak Racer.
HRTX trades at $0.3507, up 6.21% in the last 24 hours, but technical indicators signal a bearish trend overall. The company reported Q2 2026 revenue of $37.7 million, missing estimates, with a net loss per share of $0.03. Despite a high gross profit margin of 70.07%, negative net income and cash flow from operations highlight financial strain. Analyst consensus remains strongly bullish with 94.74% buy ratings, but recent news includes a Zacks Strong Sell designation on July 15, 2026.
The outlook is mixed: strong analyst support contrasts with weak earnings and bearish technicals. Investment opportunity lies in potential turnaround if revenue growth accelerates, but risks include persistent losses, competitive pressures, and reliance on financing activities. The stock faces significant downside if operational performance does not improve.
Trailing returns across standard periods
Latest headlines on both assets
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →